Trials / Completed
CompletedNCT00030966
Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab, When Added to Avonex® (Interferon Beta-1a), in Subjects With Relapsing-Remitting Multiple Sclerosis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,200 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if natalizumab in combination with AVONEX is safe and effective in delaying progression of individuals diagnosed with relapsing remitting Multiple Sclerosis (MS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Natalizumab | Natalizumab, 300 mg, monthly IV infusion for up to 116 weeks. |
| DRUG | Placebo | Placebo monthly infusion for up to 116 weeks. |
Timeline
- Start date
- 2002-01-01
- Primary completion
- 2005-04-01
- Completion
- 2005-12-01
- First posted
- 2002-02-18
- Last updated
- 2009-06-18
Locations
88 sites across 7 countries: United States, Austria, Belgium, France, Germany, Israel, Italy
Source: ClinicalTrials.gov record NCT00030966. Inclusion in this directory is not an endorsement.